Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07632352
Recruiting Not applicable

Evaluation of Clinical Effect of Acupuncture on Acute Exacerbation of Bronchial Asthma

NCT07632352 · tracked via the Priya Life Science China tracker
Sponsor
Henan University of Traditional Chinese Medicine
Phase
Not applicable
Started
2025-04-15
Last updated
2026-06-08

Condition(s) studied

Bronchial Asthma

Investigational drug(s) / intervention(s)

AcupunctureStandard Western medicine treatment

Acupuncture: The acupoints selected were Kechuan point, New Kechuan point, and Yuji point. The treatment was administered once a day for 20 minutes each time, for 5 consecutive days.

Standard Western medicine treatment: Evaluate and manage in accordance with the Chinese Expert Consensus on Assessment and Management of Acute Exacerbation of Bronchial Asthma issued by the Asthma Group of the Chinese Thoracic Society, Chinese Medical Association in 2018 and the Guidelines for the Prevention and Treatment of Bronchial Asthma (2020 ).

Study summary

Based on the bioholographic theory, this study preliminarily explores the clinical efficacy of hand acupuncture in treating acute exacerbation of bronchial asthma and evaluates its immediate anti-asthmatic effect, so as to provide a new therapeutic strategy for the clinical management of bronchial asthma.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients meeting the Western medicine diagnostic criteria for acute exacerbation of bronchial asthma 2. Aged ≥ 18 years old 3. Voluntarily receive treatment and sign the informed consent form Exclusion Criteria: 1. Those who fail to meet the inclusion criteria 2. Patients suffering from other severe systemic diseases such as diseases of the circulatory system, hematological system and nervous system 3. Pregnant or lactating women 4. Subjects enrolled but not treated per the study protocol 5. Patients who have participated in other clinical trials of medicinal products within 3 months 6. Other circumstances deemed ineligible for enrollment by researchers

Primary outcome measure(s)

  • Peak Expiratory Flow(PEF) — After treatment on Day 5 and follow-up at 1, 2 and 3 months
    PEF will be used to assess pulmonary function
  • Asthma Control Test — After treatment on Day 5 and follow-up at 1, 2 and 3 months
    The ACT score consists of 5 questions, each scored from 1 to 5 points, with a total score ranging from 5 to 25 points; lower scores indicate more severe symptoms.

Trial sites (1)

FacilityCityRegionStatus
the First Affiliated Hospital of Henan University of Chinese Medicine Zhengzhou Henan Recruiting

More Henan University of Traditional Chinese Medicine trials in China

Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome Starting soon
Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF Recruiting
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma) Starting soon
Clinical Study on the Treatment of Chronic Airway Diseases (Asthma, Chronic Obstructive Pulmonary Disease) with Shu Fei Tie Starting soon
Study on the Mechanism of Yifei Moxibustion Improving Immune Function in COPD Based on Plasma Exosome miRNAs Recruiting

Other trials for the same condition

Study on the Safety and Efficacy of PA9159 Inhalation Aerosol for the Treatment of Adult Bronchial Asthma Recruiting
REspiratory diSEAse cohoRt Studies of CHinese Medicine for Asthma (RESEARCH- Asthma) Starting soon
A Trial on the Treatment of Bronchial Asthma With Budesonide Formoterol Combined With Immune Modulators (Staphylococcus and Neisseria Tablets) Starting soon
Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy Starting soon
FeNO Detection in Asthma Diagnosis: A New Technology Approach Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07632352 on ClinicalTrials.gov ↗ ← All trials in China